Company profile
IN8BIO, INC.
NASDAQ:INABBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05664243 | phase1_2 | active_not_recruiting | 2023-09-08 | 2025-12-01 | In8bio Inc. | A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma |
FDA applications (0)
No records yet.